Sionna Therapeutics (NASDAQ:SION) Director Peter Thompson Sells 1,890 Shares

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Peter Thompson sold 1,890 shares of the business’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $44.57, for a total value of $84,237.30. Following the transaction, the director directly owned 3,559,765 shares in the company, valued at $158,658,726.05. This trade represents a 0.05% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Sionna Therapeutics Stock Down 7.1%

Shares of SION traded down $3.17 during midday trading on Wednesday, reaching $41.31. The company had a trading volume of 313,154 shares, compared to its average volume of 292,641. Sionna Therapeutics, Inc. has a 1-year low of $7.26 and a 1-year high of $45.00. The firm has a 50 day simple moving average of $41.40 and a 200-day simple moving average of $32.80. The stock has a market cap of $1.84 billion and a PE ratio of -8.48.

Sionna Therapeutics (NASDAQ:SION) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.06.

Hedge Funds Weigh In On Sionna Therapeutics

Several hedge funds have recently bought and sold shares of SION. Jennison Associates LLC boosted its holdings in Sionna Therapeutics by 11.8% during the 4th quarter. Jennison Associates LLC now owns 1,115,278 shares of the company’s stock valued at $45,883,000 after acquiring an additional 117,903 shares during the period. UBS Group AG lifted its position in shares of Sionna Therapeutics by 91.1% during the fourth quarter. UBS Group AG now owns 89,177 shares of the company’s stock worth $3,669,000 after purchasing an additional 42,511 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Sionna Therapeutics by 3.7% during the fourth quarter. Vanguard Group Inc. now owns 1,184,951 shares of the company’s stock worth $48,749,000 after purchasing an additional 41,797 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of Sionna Therapeutics by 105.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,272 shares of the company’s stock valued at $423,000 after purchasing an additional 5,272 shares during the period. Finally, GF Fund Management CO. LTD. acquired a new position in shares of Sionna Therapeutics in the fourth quarter valued at approximately $36,000.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on SION shares. Raymond James Financial restated a “strong-buy” rating and set a $53.00 price target on shares of Sionna Therapeutics in a report on Monday, January 5th. Lifesci Capital assumed coverage on Sionna Therapeutics in a research note on Tuesday, December 23rd. They set an “outperform” rating and a $60.00 target price for the company. Weiss Ratings restated a “sell (e+)” rating on shares of Sionna Therapeutics in a research report on Monday, December 29th. Wall Street Zen upgraded Sionna Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, December 13th. Finally, Royal Bank Of Canada restated an “underperform” rating and issued a $24.00 price objective on shares of Sionna Therapeutics in a report on Monday, December 1st. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $45.43.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.